Randomized trial investigates outcomes in esophageal cancer patients with uncertain responses after neoadjuvant chemoradiotherapy, suggesting surgery benefits.
Key Points
This study aims to evaluate the pathological outcomes of patients with uncertain tumor responses after neoadjuvant chemoradiotherapy for esophageal cancer.
Included patients from the SANO cohort with uncertain tumor responses after neoadjuvant chemoradiotherapy.
Primary endpoint was the complete pathological response rate after surgery.
209 total patients with uncertain responses were considered, out of which 205 underwent esophagectomy.
15% of patients had a complete pathological response after resection (95% CI 10-20).
Complete response rates were 26% for non-traversable lesions, 10% for high-grade dysplasia, and 8% for clinical suspicion groups.
33% response for patients with squamous cell carcinoma and non-traversable lesions (95% CI 21-48).